By Chris Wack

Synthorx Inc. (THOR) shares were up 165% to $66.28 premarket after Sanofi SA (SAN.FR) said it was buying the clinical-stage biotechnology for $68 a share in cash.

The deal has an equity value of about $2.5 billion, and is expected to close in the first quarter of next year.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 09, 2019 07:08 ET (12:08 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Synthorx (NASDAQ:THOR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Synthorx
Synthorx (NASDAQ:THOR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Synthorx